Редактирование: ANGPTL2

Angiopoietin-related protein 2 precursor (Angiopoietin-like protein 2) [ARP2] [UNQ170/PRO196]

==Publications==

{{medline-entry
|title=Circulating angiopoietin-like protein 2 levels and arterial stiffness in patients receiving maintenance hemodialysis: A cross-sectional study.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/33197687
|abstract=Chronic low-grade inflammation is receiving much attention as a critical pathology that induces various aging phenotypes, a concept known as "inflammaging". Uremic patients undergoing hemodialysis therapy show vascular aging phenotypes characterized by greater arterial stiffness and calcification compared to healthy controls of the same generation. In the current study, we investigated whether levels of inflammaging markers in the circulation were associated with vascular aging phenotypes in hemodialysis patients, as estimated by the cardio-ankle vascular index (CAVI). We conducted a multicenter cross-sectional study of 412 patients receiving hemodialysis and evaluated the relationship between circulating hs-[[CRP]] or [[ANGPTL2]] levels, as markers of inflammaging, and CAVI. Of 412 patients, 376 were analyzed statistically. While circulating hs-[[CRP]] levels had no significant association with CAVI, generalized linear models revealed that high circulating [[ANGPTL2]] levels were significantly associated with increasing CAVI after adjustment for classical metabolic factors and hemodialysis-related parameters [β 0.63 (95%CI 0.07-1.18)]. Exploratory analysis revealed that high circulating [[ANGPTL2]] levels were also strongly associated with increased CAVI, particularly in patients with conditions of increased vascular mechanical stress, such elevated blood pressure [β 1.00 (95%CI 0.23-1.76)], elevated pulse pressure [β 0.75 (95%CI 0.52-0.98)], or excess body fluid [β 1.25 (95%CI 0.65-1.84)]. We conclude that circulating levels of [[ANGPTL2]] rather than hs-[[CRP]] are positively associated with CAVI in the uremic population and that [[ANGPTL2]] could be a unique marker of progression of vascular aging in patients receiving hemodialysis.

|keywords=* Angiopoietin-like protein (ANGPTL) 2
* Cardio-ankle vascular index (CAVI)
* Chronic inflammation
* Hemodialysis
* Senescence
|full-text-url=https://sci-hub.do/10.1016/j.atherosclerosis.2020.10.890
}}
{{medline-entry
|title=Circulating angiopoietin-like protein 2 levels and mortality risk in patients receiving maintenance hemodialysis: a prospective cohort study.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/31840173
|abstract=Patients undergoing hemodialysis treatment have a poor prognosis, as many develop premature aging. Systemic inflammatory conditions often underlie premature aging phenotypes in uremic patients. We investigated whether angiopoietin-like protein 2 (ANGPTL 2), a factor that accelerates the progression of aging-related and noninfectious inflammatory diseases, was associated with increased mortality risk in hemodialysis patients. We conducted a multicenter prospective cohort study of 412 patients receiving maintenance hemodialysis and evaluated the relationship between circulating [[ANGPTL2]] levels and the risk for all-cause mortality. Circulating [[ANGPTL2]] levels were log-transformed to correct for skewed distribution and analyzed as a continuous variable. Of 412 patients, 395 were included for statistical analysis. Time-to-event data analysis showed high circulating [[ANGPTL2]] levels were associated with an increased risk for all-cause mortality after adjustment for age, sex, hemodialysis vintage, nutritional status, metabolic parameters and circulating high-sensitivity C-reactive protein levels {hazard ratio [HR] 2.04 [95% confidence interval (CI) 1.10-3.77]}. High circulating [[ANGPTL2]] levels were also strongly associated with an increased mortality risk, particularly in patients with a relatively benign prognostic profile [HR 3.06 (95% CI 1.86-5.03)]. Furthermore, the relationship between circulating [[ANGPTL2]] levels and mortality risk was particularly strong in patients showing few aging-related phenotypes, such as younger patients [HR 7.99 (95% CI 3.55-18.01)], patients with a short hemodialysis vintage [HR 3.99 (95% CI 2.85-5.58)] and nondiabetic patients [HR 5.15 (95% CI 3.19-8.32)]. We conclude that circulating [[ANGPTL2]] levels are positively associated with mortality risk in patients receiving maintenance hemodialysis and that [[ANGPTL2]] could be a unique marker for the progression of premature aging and subsequent mortality risk in uremic patients, except those with significant aging-related phenotypes.
|mesh-terms=* Aged
* Angiopoietin-like Proteins
* Biomarkers
* C-Reactive Protein
* Disease Progression
* Female
* Humans
* Kidney Diseases
* Male
* Middle Aged
* Prognosis
* Prospective Studies
* Renal Dialysis
* Risk Factors
* Survival Rate
|keywords=* aging
* angiopoietin-like protein (ANGPTL) 2
* chronic inflammation
* hemodialysis
* mortality risk
|full-text-url=https://sci-hub.do/10.1093/ndt/gfz236
}}
{{medline-entry
|title=Age-dependent increase in angiopoietin-like protein 2 accelerates skeletal muscle loss in mice.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29191837
|abstract=Skeletal muscle atrophy, or sarcopenia, is commonly observed in older individuals and in those with chronic disease and is associated with decreased quality of life. There is recent medical and broad concern that sarcopenia is rapidly increasing worldwide as populations age. At present, strength training is the only effective intervention for preventing sarcopenia development, but it is not known how this exercise regimen counteracts this condition. Here, we report that expression of the inflammatory mediator angiopoietin-like protein 2 ([[ANGPTL2]]) increases in skeletal muscle of aging mice. Moreover, in addition to exhibiting increased inflammation and accumulation of reactive oxygen species (ROS), denervated atrophic skeletal muscles in a mouse model of denervation-induced muscle atrophy had increased [[ANGPTL2]] expression. Interestingly, mice with a skeletal myocyte-specific [i]Angptl2[/i] knockout had attenuated inflammation and ROS accumulation in denervated skeletal muscle, accompanied by increased satellite cell activity and inhibition of muscular atrophy compared with mice harboring wildtype [i]Angptl2[/i] Moreover, consistent with these phenotypes, wildtype mice undergoing exercise training displayed decreased [[ANGPTL2]] expression in skeletal muscle. In conclusion, [[ANGPTL2]] up-regulation in skeletal myocytes accelerates muscle atrophy, and exercise-induced attenuation of [[ANGPTL2]] expression in those tissues may partially explain how exercise training prevents sarcopenia.
|mesh-terms=* Aging
* Angiopoietin-like Proteins
* Animals
* Female
* Male
* Mice
* Mice, Knockout
* Muscle Fibers, Skeletal
* Muscle, Skeletal
* Physical Conditioning, Animal
* Sarcopenia
* Up-Regulation
|keywords=* ANGPTL2
* aging
* catalase
* exercise
* inflammation
* muscle atrophy
* reactive oxygen species (ROS)
* sarcopenia
* satellite cell
* senescence
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798292
}}